{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:44:15Z","timestamp":1795088655254,"version":"4.10.2"},"reference-count":24,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,7,11]],"date-time":"2002-07-11T00:00:00Z","timestamp":1026345600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:p><jats:bold>Summary:<\/jats:bold><jats:bold> \u2002Purpose: <\/jats:bold> To evaluate the potential pharmacokinetic interactions between topiramate (TPM) and phenytoin (PHT) in patients with epilepsy by studying their pharmacokinetics (PK) after monotherapy and concomitant TPM\/PHT treatment.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Twelve patients with epilepsy stabilized on PHT monotherapy were enrolled in this study, with 10 and seven patients completing the phases with 400 and 800 mg TPM daily doses, respectively. TPM was added at escalating doses, and after stabilization at the highest tolerated TPM dose, PHT doses were tapered. Serial blood and urine samples were collected for PK analysis during the monotherapy phase or the lowest PHT dose after taper and the concomitant TPM\/PHT phase. Potential metabolic interaction between PHT and TPM also was studied in vitro in human liver microsomal preparations.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In nine of the 12 patients, PHT plasma concentrations remained stable, with a mean (\u00b1SD) area under the curve (AUC) ratio (combination therapy\/monotherapy) of 1.13 \u00b1 0.17 (range, 0.89\u20131.23). Three patients had AUC ratios of 1.25, 1.39, and 1.55, respectively, and with the addition of TPM (800, 400, and 400 mg daily, respectively), their peak PHT plasma concentrations increased from 15 to 21 mg\/L, 28 to 36 mg\/L, and 27 to 41 mg\/L, respectively. Human liver microsomal studies with <jats:italic>S<\/jats:italic>\u2010mephenytoin showed that TPM partially inhibited CYP2C19 at very high concentrations of 300 \u03bc<jats:italic>M<\/jats:italic> (11% inhibition) and 900 \u03bc<jats:italic>M<\/jats:italic> (29% inhibition). Such high plasma concentrations would correspond to doses in humans that are 5 to 15 times higher than the recommended dose (200\u2013400 mg). TPM clearance was approximately twofold higher during concomitant TPM\/PHT therapy<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This study provides evidence that the addition of TPM to PHT generally does not cause clinically significant PK interaction. PHT induces the metabolism of TPM, causing increased TPM clearance, which may require TPM dose adjustments when PHT therapy is added or is discontinued. TPM may affect PHT concentrations in a few patients because of inhibition by TPM of the CYP2C19\u2010mediated minor metabolic pathway of PHT.<\/jats:p>","DOI":"10.1046\/j.1528-1157.2002.41701.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T20:02:29Z","timestamp":1047412949000},"page":"691-696","source":"Crossref","is-referenced-by-count":67,"title":["Topiramate and Phenytoin Pharmacokinetics During Repetitive Monotherapy and Combination Therapy to Epileptic\u2003Patients"],"prefix":"10.1111","volume":"43","author":[{"given":"R.\u2003C.","family":"Sachdeo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.\u2003K.","family":"Sachdeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.\u2003H.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.\u2003J.","family":"Streeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.\u2003E.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.\u2003L.","family":"Kunze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.\u2003G.","family":"Mather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.\u2003K.","family":"Roskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.\u2003D.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.\u2003E.","family":"Thummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.\u2003F.","family":"Trager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.\u2003R.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis\u2003R.","family":"Doose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.\u2003G.","family":"Gisclon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Bialer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,7,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00388a023"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1994.tb02459.x"},{"key":"e_1_2_5_4_2","first-page":"1063","volume-title":"Antiepileptic drugs.","author":"Ben\u2010Menachem","year":"1995"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00171-6"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1996.tb04754.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02174.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200003338965"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb00651.x"},{"issue":"8","key":"e_1_2_5_10_2","first-page":"54","article-title":"The steady state (SS) pharmacokinetics (PK) of phenytoin and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy.","volume":"35","author":"Gisclon LG","year":"1994","journal-title":"Epilepsia"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","unstructured":"Anderson G. A mechanistic approach to antiepileptic drug interactions.Ann Pharmacother1998:32:554\u201363.","DOI":"10.1345\/aph.17332"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01123.x"},{"key":"e_1_2_5_13_2","first-page":"S19","article-title":"A capillary GC assay with NPD detection for the quantification of topiramate in human plasma.","volume":"8","author":"Cooper JM","year":"1991","journal-title":"Pharm Res"},{"key":"e_1_2_5_14_2","first-page":"350","article-title":"Human liver microsomal enflurane defluorination catalyzed by cytochrome P\u2010450 2E1.","volume":"21","author":"Thummel KE","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_2_5_16_2","first-page":"303","article-title":"The spectrophotometric measurement of turbid suspensions of cytochromes associated with drug metabolism.","volume":"2","author":"Estabrook RW","year":"1972","journal-title":"Methods Pharmacol"},{"key":"e_1_2_5_17_2","unstructured":"Roskos LK. Inhibition of the hepatic metabolism of (S)\u2010propranolol by uremic blood constituents. Dissertation University of Washington Seattle 1994."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm00114a019"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1993.1506"},{"key":"e_1_2_5_20_2","first-page":"610","article-title":"The formation of (R)\u20108\u2010hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)\u2010mephenytoin hydroxylase.","volume":"24","author":"Wienkers LC","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01068419"},{"key":"e_1_2_5_22_2","first-page":"329","volume-title":"Antiepileptic drugs.","author":"Levy RH","year":"1995"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1684"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00721.x"},{"key":"e_1_2_5_25_2","first-page":"1401","article-title":"Roles of cytochromes P4502C9 and cytochrome P4502C19 in stereoselective metabolism of phenytoin to its major metabolite.","volume":"24","author":"Bajpai N","year":"1996","journal-title":"Drug Metab Dispos"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1528-1157.2002.41701.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1528-1157.2002.41701.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:54:56Z","timestamp":1695869696000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1528-1157.2002.41701.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1046\/j.1528-1157.2002.41701.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1528-1157.2002.41701.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}